BIOA Stock Price, Chart, Stats & News
BioAge Labs Inc. (BIOA) does not currently pay a dividend.
BIOA chart
Fundamentals
Gross margin | 99.23% |
Operating margin | -1031.46% |
Pretax margin | -896.11% |
Net margin | -896.11% |
Effective tax rate | – |
ROA | -27.33% |
ROE | -27.86% |
D/E | 0.02x |
Interest coverage ratio | -133.11x |
BIOA valuation
P/E | – |
P/S | 64.60x |
P/B | 2.13x |
P/CF | -7.11x |
P/FCF | -7.06x |
P/OCF | -7.11x |
PEG | -0.20x |
EV multiple | -9.28x |
About
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration.
Similar securities
Based on sector and market capitalization
